Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer

被引:103
作者
Kays, Joshua K. [1 ]
Shahda, Safi [2 ,7 ,8 ]
Stanley, Melissa [2 ]
Bell, Teresa M. [1 ]
O'Neill, Bert H. [2 ,8 ]
Kohli, Marc D. [3 ]
Couch, Marion E. [4 ,7 ,8 ]
Koniaris, Leonidas G. [1 ,7 ,8 ]
Zimmers, Teresa A. [1 ,5 ,6 ,7 ,8 ]
机构
[1] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Hematol Oncol, Indianapolis, IN 46202 USA
[3] Univ Calif San Francisco, Sch Med, Dept Radiol, San Francisco, CA 94143 USA
[4] Indiana Univ Sch Med, Dept Otolaryngol Head & Neck Surg, Indianapolis, IN 46202 USA
[5] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA
[6] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA
[7] IUPUI Ctr Cachexia Res Innovat & Therapy, Indianapolis, IN USA
[8] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
基金
美国国家卫生研究院;
关键词
Cachexia; Pancreatic cancer; Sarcopenia; FOLFIRINOX; Muscle wasting; SKELETAL-MUSCLE; ADIPOSE-TISSUE; WEIGHT-LOSS; CHEMOTHERAPY; OBESITY; INHIBITION; PREVALENCE; SARCOPENIA; DEPLETION; OUTCOMES;
D O I
10.1002/jcsm.12307
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background By the traditional definition of unintended weight loss, cachexia develops in similar to 80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin therapy. Methods We performed a retrospective review of 53 patients with advanced PDAC on 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin as first line therapy at Indiana University Hospital from July 2010 to August 2015. Demographic, clinical, and survival data were collected. Body composition measurement by computed tomography (CT), trend, univariate, and multivariate analysis were performed. Results Among all patients, three cachexia phenotypes were identified. The majority of patients, 64%, had Muscle and Fat Wasting (MFW), while 17% had Fat-Only Wasting (FW) and 19% had No Wasting (NW). NW had significantly improved overall median survival (OMS) of 22.6months vs. 13.0months for FW and 12.2months for MFW (P = 0.02). FW (HR = 5.2; 95% confidence interval = 1.5-17.3) and MFW (HR = 1.8; 95% confidence interval = 1.1-2.9) were associated with an increased risk of mortality compared with NW. OMS and risk of mortality did not differ between FW and MFW. Progression of disease, sarcopenic obesity at diagnosis, and primary tail tumours were also associated with decreased OMS. On multivariate analysis, cachexia phenotype and chemotherapy response were independently associated with survival. Notably, CT-based body composition analysis detected tissue loss of >5% in 81% of patients, while the traditional definition of >5% body weight loss identified 56.6%. Conclusions Distinct cachexia phenotypes were observed in this homogeneous population of patients with equivalent stage, diagnosis, and first-line treatment. This suggests cellular, molecular, or genetic heterogeneity of host or tumour. Survival among patients with FW was as poor as for MFW, indicating adipose tissue plays a crucial role in cachexia and PDAC mortality. Adipose tissue should be studied for its mechanistic contributions to cachexia.
引用
收藏
页码:673 / 684
页数:12
相关论文
共 45 条
  • [1] [Anonymous], 2016, OB OV
  • [2] Cancer cachexia, mechanism and treatment
    Aoyagi, Tomoyoshi
    Terracina, Krista P.
    Raza, Ali
    Matsubara, Hisahiro
    Takabe, Kazuaki
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 7 (04) : 17 - 29
  • [3] ARGILES JM, 2006, CACHEXIA WASTING MOD
  • [4] 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
    Assaf, Elias
    Verlinde-Carvalho, Muriel
    Delbaldo, Catherine
    Grenier, Julien
    Sellam, Zineb
    Pouessel, Damien
    Bouaita, Linda
    Baumgaertner, Isabelle
    Sobhani, Iradj
    Tayar, Claude
    Paul, Muriel
    Culine, Stephane
    [J]. ONCOLOGY, 2011, 80 (5-6) : 301 - 306
  • [5] Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways
    Barreto, Rafael
    Mandili, Giorgia
    Witzmann, Frank A.
    Novelli, Francesco
    Zimmers, Teresa A.
    Bonetto, Andrea
    [J]. FRONTIERS IN PHYSIOLOGY, 2016, 7
  • [6] Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs
    Barreto, Rafael
    Waning, David L.
    Gao, Hongyu
    Liu, Yunlong
    Zimmers, Teresa A.
    Bonetto, Andrea
    [J]. ONCOTARGET, 2016, 7 (28) : 43442 - 43460
  • [7] Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model-a study based on data from an international multicentre project (EPCRC-CSA)
    Blum, D.
    Stene, G. B.
    Solheim, T. S.
    Fayers, P.
    Hjermstad, M. J.
    Baracos, V. E.
    Fearon, K.
    Strasser, F.
    Kaasa, S.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (08) : 1635 - 1642
  • [8] JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia
    Bonetto, Andrea
    Aydogdu, Tufan
    Jin, Xiaoling
    Zhang, Zongxiu
    Zhan, Rui
    Puzis, Leopold
    Koniaris, Leonidas G.
    Zimmers, Teresa A.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2012, 303 (03): : E410 - E421
  • [9] STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia
    Bonetto, Andrea
    Aydogdu, Tufan
    Kunzevitzky, Noelia
    Guttridge, Denis C.
    Khuri, Sawsan
    Koniaris, Leonidas G.
    Zimmers, Teresa A.
    [J]. PLOS ONE, 2011, 6 (07):
  • [10] Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer
    Boone, Brian A.
    Steve, Jennifer
    Krasinskas, Alyssa M.
    Zureikat, Amer H.
    Lembersky, Barry C.
    Gibson, Michael K.
    Stoller, Ronald G.
    Zeh, Herbert J.
    Bahary, Nathan
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2013, 108 (04) : 236 - 241